JP2021514661A5 - - Google Patents

Info

Publication number
JP2021514661A5
JP2021514661A5 JP2020546407A JP2020546407A JP2021514661A5 JP 2021514661 A5 JP2021514661 A5 JP 2021514661A5 JP 2020546407 A JP2020546407 A JP 2020546407A JP 2020546407 A JP2020546407 A JP 2020546407A JP 2021514661 A5 JP2021514661 A5 JP 2021514661A5
Authority
JP
Japan
Prior art keywords
seq
cancer
peptide
polypeptide
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020546407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514661A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/020685 external-priority patent/WO2019173289A1/en
Publication of JP2021514661A publication Critical patent/JP2021514661A/ja
Publication of JP2021514661A5 publication Critical patent/JP2021514661A5/ja
Priority to JP2024035825A priority Critical patent/JP2024069367A/ja
Pending legal-status Critical Current

Links

JP2020546407A 2018-03-05 2019-03-05 サイトカインに連結させたecm親和性ペプチドを用いてがんを処置するための方法および組成物 Pending JP2021514661A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024035825A JP2024069367A (ja) 2018-03-05 2024-03-08 サイトカインに連結させたecm親和性ペプチドを用いてがんを処置するための方法および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862638520P 2018-03-05 2018-03-05
US62/638,520 2018-03-05
US201862727156P 2018-09-05 2018-09-05
US62/727,156 2018-09-05
PCT/US2019/020685 WO2019173289A1 (en) 2018-03-05 2019-03-05 Methods and compositions for treating cancer with ecm-affinity peptides linked to cytokines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024035825A Division JP2024069367A (ja) 2018-03-05 2024-03-08 サイトカインに連結させたecm親和性ペプチドを用いてがんを処置するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2021514661A JP2021514661A (ja) 2021-06-17
JP2021514661A5 true JP2021514661A5 (cg-RX-API-DMAC7.html) 2022-03-14

Family

ID=67847453

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020546407A Pending JP2021514661A (ja) 2018-03-05 2019-03-05 サイトカインに連結させたecm親和性ペプチドを用いてがんを処置するための方法および組成物
JP2024035825A Pending JP2024069367A (ja) 2018-03-05 2024-03-08 サイトカインに連結させたecm親和性ペプチドを用いてがんを処置するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024035825A Pending JP2024069367A (ja) 2018-03-05 2024-03-08 サイトカインに連結させたecm親和性ペプチドを用いてがんを処置するための方法および組成物

Country Status (7)

Country Link
US (2) US12365714B2 (cg-RX-API-DMAC7.html)
EP (1) EP3762407A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021514661A (cg-RX-API-DMAC7.html)
CN (1) CN112292391A (cg-RX-API-DMAC7.html)
AU (2) AU2019232729B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020018196A2 (cg-RX-API-DMAC7.html)
WO (1) WO2019173289A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
SG11202100935TA (en) * 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
EP3930687A4 (en) * 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
CN114206355A (zh) 2019-06-03 2022-03-18 芝加哥大学 用靶向癌症的佐剂治疗癌症的方法和组合物
WO2021174121A1 (en) * 2020-02-27 2021-09-02 Icahn School Of Medicine At Mount Sinai Vegfr-3-activating agents and oncolytic viruses and uses thereof for the treatment of cancer
EP4262840A4 (en) * 2020-12-18 2024-11-20 Cullinan Amber Corp. IMMUNOMODULATORY MOLECULES LOCALIZED IN BI-FUNCTIONAL LINEAR FUSION COLLAGEN AND THEIR METHODS
CN113350522B (zh) * 2021-05-21 2022-08-30 浙江大学杭州国际科创中心 一种铂铜合金/氯离子转运体复合肿瘤治疗制剂及其制备方法、应用
CN116999539A (zh) * 2022-04-28 2023-11-07 天津大学 结直肠癌免疫治疗药物ifnbcol01
EP4739334A1 (en) 2023-07-05 2026-05-13 Nanotein Technologies, Inc. Cell signaling complexes and uses thereof
US12473529B2 (en) 2023-07-18 2025-11-18 Nanotein Technologies, Inc. Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof
WO2025245169A1 (en) * 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US6103379A (en) 1994-10-06 2000-08-15 Bar-Ilan University Process for the preparation of microspheres and microspheres made thereby
US6211159B1 (en) 1997-04-11 2001-04-03 University Of Toronto Flagellin gene, FlaC of campylobacter
JP4375901B2 (ja) 1997-11-28 2009-12-02 大日本住友製薬株式会社 新規な複素環化合物
US6150022A (en) 1998-12-07 2000-11-21 Flex Products, Inc. Bright metal flake based pigments
CA2378925C (en) 1999-07-21 2010-04-06 University Of Southern California Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
WO2001016180A2 (en) 1999-08-27 2001-03-08 Board Of Regents, The University Of Texas System Cd40 agonist compositions and methods of use
US7192725B2 (en) 2000-05-19 2007-03-20 University Of Toronto Flagellin gene, flaC of Campylobacter
KR100379250B1 (ko) 2000-12-04 2003-04-08 한국과학기술연구원 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법
US20050037962A1 (en) 2002-01-18 2005-02-17 Ekker Stephen C. Syndecans and angiogenesis
NZ535952A (en) 2002-04-04 2009-01-31 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
AU2004271200A1 (en) * 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
JP2007526253A (ja) 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ,インコーポレイテッド 免疫刺激性ウイルスrnaオリゴヌクレオチド
WO2005082941A1 (en) 2004-02-27 2005-09-09 The University Of Western Ontario Bone sialoprotein collagen-binding peptides
US8273357B2 (en) 2004-07-16 2012-09-25 Massachusetts Institute Of Technology Antigen-carbohydrate conjugates
AU2006241149A1 (en) 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
WO2007062107A2 (en) 2005-11-25 2007-05-31 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
ATE514712T1 (de) 2005-12-26 2011-07-15 Yantai Zhenghai Bio Technology Co Ltd Aktivierte collagen-gerüstmaterialien und ihre speziellen kondensierten aktiven restorationsfaktoren
WO2008033432A2 (en) 2006-09-12 2008-03-20 Coley Pharmaceutical Group, Inc. Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
US20080160024A1 (en) 2006-12-07 2008-07-03 Board Of Trustees Of The University Of Arkansas Inhibition of cancer metastasis
AT504685B1 (de) 2006-12-20 2009-01-15 Protaffin Biotechnologie Ag Fusionsproteine
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2010018132A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Compounds
RU2579977C2 (ru) 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
US8734774B2 (en) 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
WO2012112690A2 (en) 2011-02-16 2012-08-23 Fabius Biotechnology Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
US9879062B2 (en) 2012-07-03 2018-01-30 Ecole Polytechnique Federale De Lausanne Protein-binding peptide isolated from placenta growth factor
WO2015124297A1 (en) * 2014-02-19 2015-08-27 Merck Patent Gmbh Cancer-targeted il-12 immunotherapy
US10420820B2 (en) 2014-09-29 2019-09-24 Counterpoint Biomedia LLC Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides
CN107073132B (zh) 2014-10-06 2021-08-27 梅约医学教育与研究基金会 载体-抗体组合物及其制备和使用方法
US20200331984A1 (en) * 2016-09-20 2020-10-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Harnessing protein-based drugs comprising an anchor domain for use on the ocular surface
WO2018184003A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
AU2018256453B2 (en) 2017-04-20 2024-02-08 The University Of Chicago Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2020041758A1 (en) 2018-08-24 2020-02-27 City Of Hope Masked cytokine conjugates
EP3930687A4 (en) * 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS

Similar Documents

Publication Publication Date Title
Yu et al. Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma
Fallon et al. The immunocytokine NHS-IL12 as a potential cancer therapeutic
US12479918B2 (en) Plasmid constructs for treating cancer and methods of use
Balza et al. Targeted Delivery of Tumor Necrosis Factor-α to Tumor Vessels Induces a Therapeutic T Cell–Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin
AU2018273958B2 (en) PD-1 and CTLA-4 dual inhibitor peptides
US7141550B2 (en) Intra-tumoral administration of IL-12 encoding nucleic acid molecules
JP2020517658A5 (cg-RX-API-DMAC7.html)
JP2024069367A (ja) サイトカインに連結させたecm親和性ペプチドを用いてがんを処置するための方法および組成物
Mantooth et al. Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies
EP4041282A1 (en) Methods of using il-33 protein in treating cancers
JP2020509737A5 (cg-RX-API-DMAC7.html)
CN118434436A (zh) 免疫刺激性mrna组合物及其用途
Yang et al. Synergy of polydopamine nanovaccine and endostar alginate hydrogel for improving antitumor immune responses against colon tumor
JP2024500870A5 (cg-RX-API-DMAC7.html)
Ziffels et al. Antibody-based delivery of cytokine payloads to carbonic anhydrase IX leads to cancer cures in immunocompetent tumor-bearing mice
WO2015075194A1 (en) Preparations and methods for treating a gd2 positive cancer
JP2020531409A (ja) ホスファチジルセリン標的化融合分子およびそれらの使用方法
JP7824885B2 (ja) 表皮水疱症の治療で使用するためのホーミングペプチド誘導デコリン複合体
EP2070547B1 (en) A composition comprising humanized anti-egfr mab h-r3 antibody and type i inf for use in treating cancer
JP2022066353A (ja) 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
JP2020500881A (ja) Pd−1シグナル伝達を調節するための組成物
CN116621966B (zh) 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用
HK40114150A (en) Immunostimulatory mrna compositions and uses thereof
Niu Locally Administered Particle-Anchored Cytokines Safely Enhance Cancer Immunotherapy
Kelly The Immunoengineering Toolbox: A Set of Thermoresponsive Biopolymers for Sustained Delivery of Cancer Immunotherapies